Get all premium features to the best stock analysis tool

NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth.

NRx Pharmaceuticals, Inc. (NRXP) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago.

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026.

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product.

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Approval of NRX-100 for a broadened indication of treating depression, including patients with suicidality.